TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2340612
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 0.5 ml.kg‐1 of bupivacaine 0.25% following induction of anaesthesia before surgery
Study: 7182948
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of butropium bromide (BB) at doses of 10 and 15 mg
Study: 7182948
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of butropium bromide (BB) at doses of 0.25 and 0.5 mg
Study: 7182948
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of butropium bromide (BB) at doses of 0.25-2.0 mg/person
Study: 30590716
Drug: ACEi/ARBs +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi/ARBs + β-blockers
Study: 30590716
Drug: Matched controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched controls without antihypertensive treatment
Study: 28189123
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 10 mg/20 mg
Study: 28189123
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 120 μg/240 μg
Study: 28189123
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NETA) 5 mg/10 mg
Study: 28189123
Drug: Nestorone® (NES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone® (NES) 2 mg/3 mg
Study: 28189123
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (T)
Study: 28189123
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of progestins with transdermal testosterone
Study: 11904596
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive
Study: 23378537
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with educational materials (EMs)
Study: 21088596
Drug: Protective OLV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective OLV with tidal volume 6 ml/kg, FIO2 of 0.5, PEEP of 5 cmH2O
Study: 21088596
Drug: Conventional OLV
Normalized name: Olvimulogene nanivacirepvec
DrugBank: Olvimulogene nanivacirepvec (DB16268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional OLV with tidal volume 10 ml/kg, FIO2 of 1.0, no PEEP
Study: 19552728
Drug: Ibandronate 6
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 6 mg intravenous every 4 weeks for 24 months
Study: 12900686
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) ingestion (6.4%, 64 g x L‐1)
Study: 10870740
Drug: Older generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older generation antidepressants (e.g., amitriptyline, nortriptyline)
Study: 10870740
Drug: Anticonvulsant (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant (e.g., gabapentin)
Study: 16086149
Drug: Chronic opioid
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic opioid therapy
Study: 1643195
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg/70 kg
Study: 1643195
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg/70 kg
Study: 1643195
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 or 10 mg/70 kg)
Study: 6487547
Drug: Minutes' therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minutes' therapy with dithranol in Lassar's paste
Study: 6487547
Drug: Short-contact therapy
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-contact therapy with dithranol in Lassar's paste
Study: 18824931
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg x kg(‐1))
Study: 21730779
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid combination treatment for 10 days after abscess drainage
Study: 21730779
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 10 days after abscess drainage
Study: 19074638
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral exposure (10 s)
Study: 15589853
Drug: Recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant LH in addition to increased dose of FSH (group B)
Study: 15589853
Drug: Increased dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosage of FSH (group A)
Study: 15589853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (D) with no need to increase FSH dose
Study: 11694700
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin V
Study: 8502522
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G
Study: 8502522
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin estolate
Study: 14665353
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily) for 30 days before biopsy
Study: 14665353
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tamsulosin treatment)
Study: 12823087
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b therapy (5 million units 3 times per week or 3 to 5 million units 3 times per week with ribavirin 1000-1200 mg/day)
Study: 2079571
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b therapy
Study: 8892128
Drug: Discharge planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discharge planning and 8-week home follow-up provided by advanced practice nurses, including home visits, telephone outreach, and daily telephone availability.
Study: 2059530
Drug: Conventional toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional toothbrush (Oral B 32)
Study: 26979312
Drug: T-DM1 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 3.6 mg/kg every three weeks or 2.4 mg/kg weekly + paclitaxel 80 mg/m2 weekly ± pertuzumab 840 mg loading dose followed by 420 mg q3w
Study: 24660647
Drug: Red laser
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red laser therapy (4 J/cm2 in temporomandibular joints and 8 J/cm2 in muscles, three sessions)
Study: 24660647
Drug: Infrared laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared laser therapy (4 J/cm2 in temporomandibular joints and 8 J/cm2 in muscles, three sessions)
Study: 21593809
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 µg sodium selenite/day for 3 weeks)
Study: 20504899
Drug: Mixed insulins
Normalized name: insulin aspart protamine, human / insulin aspart, human Injectable Suspension [NovoLog Mix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed insulins (insulin detemir mixed with aspart)
Study: 20504899
Drug: Separate insulins
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Separate insulins (insulin detemir and aspart given separately)
Study: 17631952
Drug: Omalizumab +
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab + Ragweed immunotherapy
Study: 17631952
Drug: Ragweed immunotherapy
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed immunotherapy alone
Study: 9706918
Drug: Lorazepam 60
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam 60 microg/kg p.o. (Group L)
Study: 9706918
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg/kg plus scopolamine 6 microg/kg i.m. (Group M)
Study: 2403593
Drug: Selection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection of a drug by the capillary cloning system
Study: 2403593
Drug: Selection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection of a drug by the clinician
Study: 23200303
Drug: Atomoxetine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (80 mg/day; p.o.)
Study: 11337976
Drug: CLA supplementation
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA supplementation (3.9 g/d)
Study: 2205704
Drug: pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (15 mg)
Study: 2439787
Drug: atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (100 mg)
Study: 788694
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (1 mg, orally, every 6 hours for two weeks)
Study: 788694
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prostaglandin treatment)
Study: 28693558
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of elemental zinc orally for 14 days
Study: 25182142
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g almonds
Study: 25182142
Drug: 42 g
Normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 g almonds
Study: 25182142
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g almonds)
Study: 21435092
Drug: 14-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day hybrid therapy (esomeprazole and amoxicillin for 7 days followed by esomeprazole, amoxicillin, clarithromycin, and metronidazole for 7 days)
Study: 6606421
Drug: Single 1.92g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1.92g dose of co-trimoxazole
Study: 23423302
Drug: L-arginine (ARG)
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (ARG) 6 g
Study: 23423302
Drug: L-arginine (ARG)
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (ARG) 6 g plus 25 g carbohydrate (ARG + CHO)
Study: 20872778
Drug: SB-742457 35
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-742457 35 mg/day
Study: 12875613
Drug: donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 10 mg/day
Study: 15194366
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups received tacrolimus, mycophenolate mofetil, and steroids for maintenance immunosuppression
Study: 15824681
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (HDE)
Study: 15824681
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (SDE)
Study: 1489123
Drug: Inhaled lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lidocaine (20 mg and 80 mg from nebulized solutions)
Study: 1489123
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (nebulized solutions 0.125 to 32%)
Study: 3993874
Drug: Low-volume epidural
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume epidural morphine (2 mg in 1 ml saline) administered to Group II patients upon complaint of worst pain
Study: 3993874
Drug: Low-volume epidural
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume epidural morphine (2 mg in 1 ml saline) administered to Group III patients after extubation but before pain complaint
Study: 3993874
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume epidural morphine (2 mg in 10 ml saline) administered to Group I patients upon complaint of worst pain
Study: 30985540
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (60 mg/kg)
Study: 30985540
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% saline, 100 ml)
Study: 25316559
Drug: Garlic (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (400 mg garlic and 1 mg allicin)
Study: 23595874
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg pure theobromine (TB)
Study: 23595874
Drug: Cocoa intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa intervention (CC)
Study: 23595874
Drug: Theobromine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine and cocoa intervention (TB+CC)
Study: 6669636
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zopiclone
Study: 25501294
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zopiclone
Study: 21694628
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g ethanol
Study: 18269387
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine (B5C0)
Study: 18269387
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine with 15 microg clonidine (B5C15)
Study: 18269387
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine with 30 microg clonidine (B5C30)
Study: 7506471
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (hGH) treatment (0.1 IU.kg‐1 body wt.day‐1 for 7 days)
Study: 7506471
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (hGH) treatment
Study: 29985440
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug users (including digoxin and sotalol)
Study: 29985440
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of antiarrhythmic drugs
Study: 24579970
Drug: Fasudil in
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil in addition to routine treatment
Study: 18167382
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 5 mg
Study: 18847584
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of misoprostol 800 mcg vaginally
Study: 28103816
Drug: Self-assessment instrument
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-assessment instrument (Montgomery-Asberg Depression Rating Scale) used in recurrent consultations with GPs, treatment as usual (TAU) for 3 months, with at least 4 visits.
Study: 28103816
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) without the self-assessment instrument.
Study: 21905158
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical activity counseling (PA group, n = 20) for 3 months via telephone, including weekly PA tip sheets.
Study: 21992075
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus letrozole (L + Let)
Study: 21992075
Drug: Letrozole monotherapy
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole monotherapy (Let)
Study: 19090876
Drug: Chlorthalidone 12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5-25 mg/d
Study: 19090876
Drug: Amlodipine 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5-10 mg/d
Study: 19090876
Drug: Lisinopril 10-40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-40 mg/d
Study: 9032702
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (0.1 kcal ml‐1)
Study: 9032702
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (0.7 kcal ml‐1)
Study: 9032702
Drug: Pea peptide
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea peptide hydrolysate (0.2 kcal ml‐1)
Study: 9032702
Drug: Whey peptide
Normalized name: Colostral Whey Peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey peptide hydrolysate (0.2 kcal ml‐1)
Study: 7690583
Drug: 5-hydroxy-L-tryptophan (5-HTP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxy-L-tryptophan (5-HTP, 10 micrograms kg-1 min-1)
Study: 7690583
Drug: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP, 16.6 micrograms kg-1 min-1)
Study: 3538367
Drug: 5-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-drug combination therapy (vincristine, carmustine, alkylating agents, and prednisone)
Study: 3538367
Drug: 2-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-drug combination therapy
Study: 2226737
Drug: 5-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-drug combination therapy
Study: 3538367
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy after remission
Study: 3538367
Drug: Discontinued therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued therapy after remission
Study: 3538367
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy vs Discontinued therapy
Study: 30092324
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg weekly for 16 weeks)
Study: 27716697
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) 30 mg/kg in 500 cc normal saline
Study: 27716697
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 cc normal saline)
Study: 23230645
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel (F) alone
Study: 23230645
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel (F) combined with chlorhexidine varnishes (CHX)
Study: 27770695
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment
Study: 18402625
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose (inpatients, mg) = 350.15 + 289.92 (desired lithium level, mmol/L) + 0.84 (weight, kg) - 1.76 (age, years) + 34.43 [TCA, yes = 1, no = 0] + 62.1(CL(Cr), L/h) + 13.1 [BUN, mmol/L] + 40.9 (sex, male = 1, female = 0)
Study: 18402625
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose (outpatients, mg) = 784.92 + 530.22 (desired lithium level, mmol/L) + 8.61 (weight, kg) - 12.09 (age, years) - 11.14 (TCA, yes = 1, no = 0) - 7.63 (CL(Cr), L/h) - 42.62 (BUN, mmol/L) - 23.43 (sex, male = 1, female = 0)
Study: 15808751
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of phVEGF-A(165)
Study: 20009522
Drug: DTPa-HBV-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV/Hib vaccine
Study: 12424582
Drug: DTPa-IPV/Hib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV/Hib and HBV vaccines (comparator)
Study: 12285561
Drug: 3 applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 applications of 36 mg quinacrine hydrochloride pellets during the proliferative phase of 3 consecutive menstrual cycles
Study: 6234966
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg rosoxacin by mouth (group B)
Study: 6234966
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g spectinomycin administered intramuscularly (group A)
Study: 24877116
Drug: Usual balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual balance therapy
Study: 20153389
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) mixed with porridge
Study: 12225494
Drug: Parachute group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parachute group (intensive psychosocial treatment and support)
Study: 7355429
Drug: Anticoagulant (AC)
Normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant (AC) treatment
Study: 31056413
Drug: Anti-platelet therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-platelet therapy